Early Access — free while we kick the tires
EdgarHawk

Jacobson Allan Steven

Director

Director
1 filing analyzed · 1 company · Latest 2025-11-26

Companies

Company Buys Sells Direction
PTC THERAPEUTICS, INC. PTCT 0 14 Net selling

Activity

November 2025
2025-11-26 PTC THERAPEUTICS, INC. PTCT
high
Sell
26,000 shares
$2,132,018
Significance 7/10

Director Jacobson sold 26,000 shares of PTCT across 10 transactions for $2,132,018.42; stock near 52-week high.

Jacobson Allan Steven executed 10 separate sales totaling 26,000 shares for $2,132,018.42 over two days (2025-11-24 to 2025-11-25), reducing his holdings by 59.8% from 43.5K to 17.5K shares. The blended average sale price was $82.00, while the current price stands at $86.25—at the 52-week high—meaning the director sold below recent market levels and has seen the stock appreciate 5.2% since transaction completion. His prior track record at PTCT (3 prior sells, all on 2023-05-11) shows a 90-day well-timed rate of 100%, with 90-day returns averaging -27.3%, -29.3%, and -30.1% post-sale. The company's fundamentals show revenue of $211,007,000 with net income of $15,896,000, but annual revenue growth was -14.0% and the company was unprofitable over its most recent full fiscal year, despite a low P/E of 9.21. The timing of this large, multi-tranche sale—executed just as the stock reached its 52-week peak—warrants attention given the director's historical pattern of well-timed exits at this ticker and the company's deteriorating year-over-year revenue trend.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access